Table 1 Association of clinicopathological variables. AURKA positivity was associated with clinico-pathological variables and staing of AR, Ki67, EZH2 and PTEN expression levels in AR positive pros-tate cancer samples (NEPCs were excluded from the analysis)
From: The expression of AURKA is androgen regulated in castration-resistant prostate cancer
Variable | AURKA expression | P | |
|---|---|---|---|
Negative | Positive | ||
Prostatectomy specimens, n (%) | 93 (88) | 13 (12) | Â |
Locally recurrent CRPCs, n (%) | 67 (53) | 59 (47) | Â |
Metastasized CRPCs, n (%)a | 81 (78) | 23 (22) | Â |
Metastasized CRPC patients, n (%)a | 11 (48) | 12 (52) | <0.0001 |
Prostatectomy specimens: | |||
Gleason score, n (%)a | |||
 <7 | 37 (92) | 3 (8) |  |
 7 | 42 (87) | 6 (13) |  |
 >7 | 8 (73) | 3 (27) | 0.204 |
pT Stage, n (%)a | |||
 pT2 | 59 (88) | 8 (12) |  |
 pT3 | 31 (86) | 5 (14) | 0.777 |
AR expression, n (%)b | |||
 weak or moderate | 13 (87) | 2 (13) |  |
 strong | 54 (83) | 11 (17) | 0.504 |
ERG expression, n (%)b | |||
 negative or weak | 48 (60) | 8 (62) |  |
 moderate or strong | 32 (40) | 5 (38) | 0.734 |
PTEN expression, n (%)b | |||
 negative or weak | 40 (56) | 7 (70) |  |
 moderate or strong | 31 (44) | 3 (30) | 0.508 |
p53 Copy number, n (%)b | |||
 normal | 48 (84) | 4 |  |
 Heterozygous deletion | 9 | 1 | 1.000 |
SPINK expression, n (%)b | |||
 negative or weak | 64 (84) | 11 (100) |  |
 moderate or strong | 12 (16) | 0 (0) | 0.349 |
 PSA ng/mL (mean +/− SD)c | 14.3 (10.1) | 15.4 (12.4) | 0.948 |
 Age (mean +/− SD)c | 63.3 (4.8) | 60.7 (5.9) | 0.126 |
 Ki-67 (mean+/− SD)c | 5.4 (3.2) | 7.7 (4.7) | 0.030 |
 EZH2 (mean +/− SD)c | 22.9 (15.2) | 23.2 (16.9) | 0.934 |
